scholarly journals Effect of non-surgical periodontal treatment on crevicular levels of Chemerin and Fibroblast growth factor 21 in controlled type 2 diabetic and non-diabetic patients both with periodontitis and their glycemic control. A clinical trial

2019 ◽  
Vol 65 (3) ◽  
pp. 122-123
Author(s):  
Wesam Abdel Moneim ◽  
Olfat Shaker ◽  
Eman Amr
Keyword(s):  
Clinical Trial ◽  
Growth Factor ◽  
Glycemic Control ◽  
Fibroblast Growth Factor ◽  
Periodontal Treatment ◽  
Fibroblast Growth Factor 21 ◽  
Diabetic Patients ◽  
Fibroblast Growth ◽  
Type 2 Diabetic

Inverse Association of Serum Fibroblast Growth Factor 19 and Atherogenic Index of Plasma in Type 2 Diabetic Patients

2020 ◽  
Author(s):  
Wangshu Liu ◽  
Tianli Xu ◽  
Mengjie Tang ◽  
Xue-Qin Wang ◽  
Jianbin Su ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Atherogenic Index ◽  
Diabetic Patients ◽  
Fibroblast Growth ◽  
Type 2 Diabetic Patients ◽  
Atherogenic Index Of Plasma ◽  
Fibroblast Growth Factor 19 ◽  
Type 2 Diabetic

Abstract BackgroundWe aimed to explore the relationship between serum fibroblast growth factor 19 (FGF19) and the atherogenic index of plasma (AIP) in type 2 diabetic patients.MethodsSerum FGF19 levels and lipid profiles were measured in 200 patients with type 2 diabetes (T2D). The levels of serum FGF19 were measured by ELISA. Lipid profiles were measured by enzymatic analysis. AIP and NAFLD fibrosis scores were calculated.ResultsT2D patients showed a significant decreasing trend of FGF19 concentrations depending on the tertiles of AIP (p for trend < 0.05). Simultaneously, the AIP level was closely related to the serum FGF19 level (p < 0.05). Furthermore, after adjusting for age, sex, duration, BMI, hypertension, and diabetic treatment, the correlation was still significant (p < 0.01), and it remained significant even after further adjusting for non-alcoholic fatty liver disease (NAFLD) and NAFLD fibrosis score (NFS) (p < 0.01). However, when stratified by BMI, AIP was positively correlated with FGF19 in normal-weight and overweight T2D patients but not in obese T2D subjects. After adjusting for sex, age, BMI, duration, hypertension, HbA1c, 2hPG, HOMA-IR, AIP, antidiabetic treatments, NAFLD and NFS via multiple stepwise linear regression, AIP was an independent factor affecting serum FGF19 concentrations (SE = 0.238, β = -0.290, p < 0.01).ConclusionsSerum FGF19 levels might be a good predictor for atherosclerosis and cardiovascular disease in T2D patients, especially among non-obese patients; serum FGF19 levels were significantly inversely associated with AIP.

scholarly journals Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus

2009 ◽  
Vol 161 (3) ◽  
pp. 391-395 ◽  
Author(s):  
Ke Li ◽  
Ling Li ◽  
Mengliu Yang ◽  
Haihong Zong ◽  
Hua Liu ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 21 ◽  
Diabetic Patients ◽  
Fibroblast Growth ◽  
Fasting Plasma

ObjectiveFibroblast growth factor-21 (FGF-21) has recently been characterized as a potent metabolic regulator, but its pathophysiologic roles in humans remain unknown. This study aimed to investigate the effects of rosiglitazone on plasma FGF-21 levels in patients with type 2 diabetes mellitus (T2DM).Design and methodsThirty patients with new-onset T2DM (nT2DM), 34 type 2 diabetic patients with poor glycemic control (pT2DM) after the treatment with single hypoglycemic agent metformin, and 30 sex- and age-matched normal glycaemic controls (NGT) participated in the study. The pT2DM group was treated with rosiglitazone for 12 weeks. Plasma FGF-21 levels were measured with a RIA. The relationship between plasma FGF-21 levels and metabolic parameters was also analyzed.ResultsFasting plasma FGF-21 levels were higher in nT2DM and pT2DM groups than in the control (1.81±0.64 vs 1.87±0.63 vs 1.52±0.61 μg/l, P<0.05), but there was no difference between nT2DM and pT2DM groups. Fasting plasma FGF-21 levels were decreased significantly in pT2DM group after the treatment with rosiglitazone compared with pre-treatment (1.59±0.63 vs 1.87±0.64 μ/l, P<0.05). In all diabetic patients, multiple regression analysis showed that HbA1c, fasting insulin, and homeostasis model assessment-insulin resistance index were independently associated with plasma FGF-21 levels.ConclusionsIn pT2DM patients, plasma FGF-21 levels are increased, but significantly decreased after the treatment with rosiglitazone on top of ongoing metformin therapy. These data suggest that rosiglitazone may play a role in lowering FGF-21 levels in T2DM patients.

Fibroblast growth factor 21 as a predictor of early stage diabetic nephropathy in type 2 diabetic mellitus

2019 ◽  
Vol 22 (07) ◽  
pp. 01-07
Author(s):  
Samah Naji ◽  
Kareem Ghali ◽  
Najah Hadi ◽  
Maysaa Ali Abdul khaleq ◽  
Mohammed Abdelhussain
Keyword(s):  
Diabetic Nephropathy ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Early Stage ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth ◽  
Diabetic Mellitus ◽  
Type 2 Diabetic Mellitus ◽  
Type 2 Diabetic

scholarly journals Fibroblast Growth Factor 21 Improves Insulin Resistance and Ameliorates Renal Injury in db/db Mice

Endocrinology ◽  
2013 ◽  
Vol 154 (9) ◽  
pp. 3366-3376 ◽  
Author(s):  
H. W. Kim ◽  
J. E. Lee ◽  
J. J. Cha ◽  
Y. Y. Hyun ◽  
J. E. Kim ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Diabetic Nephropathy ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Renal Injury ◽  
Mesangial Cells ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth ◽  
Type 2 Diabetic

Despite the emerging importance of fibroblast growth factor 21 (FGF21) as a metabolic hormone regulating energy balance, its direct effects on renal function remain unexplored. FGF21 was injected ip daily for 12 weeks into db/db mice. Compared with control vehicle injection, FGF21 treatment significantly improved lipid profiles and insulin resistance and resulted in significantly higher serum adiponectin levels. In contrast, serum insulin and 8-isoprostane levels were significantly decreased. Interestingly, FGF21 and its receptor components in the kidneys were found to be significantly up-regulated in db/db mice, which suggests an FGF21-resistant state. FGF21 treatment significantly down-regulated FGF21 receptor components and activated ERK phosphorylation. FGF21 administration also markedly decreased urinary albumin excretion and mesangial expansion and suppressed profibrotic molecule synthesis. Furthermore, FGF21 improved renal lipid metabolism and oxidative stress injury. In cultured renal cells, FGF21 was mainly expressed in mesangial cells, and knockdown of FGF21 expression by stealth small interfering RNA further aggravated high-glucose-induced profibrotic cytokine synthesis in mesangial cells. Our results suggest that FGF21 improves insulin resistance and protects against renal injury through both improvement of systemic metabolic alterations and antifibrotic effects in type 2 diabetic nephropathy. Targeting FGF21 could therefore provide a potential candidate approach for a therapeutic strategy in type 2 diabetic nephropathy.

Serum fibroblast growth factor 21 concentrations in type 2 diabetic retinopathy patients

2016 ◽  
Vol 77 (5) ◽  
pp. 586-592 ◽  
Author(s):  
Alireza Esteghamati ◽  
Alireza Momeni ◽  
Ali Abdollahi ◽  
Amirhossein Khandan ◽  
Mohsen Afarideh ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth ◽  
Type 2 Diabetic ◽  
Type 2 Diabetic Retinopathy
Sign in / Sign up

Export Citation Format

Share Document